Lead Product(s) : ETH52
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Ethris
Deal Size : Undisclosed
Deal Type : Collaboration
Ethris And Lonza Team Up For Spray-Dried mRNA Respiratory Vaccines
Details : The initial focus of the collaboration is to develop a first-in-class mRNA vaccine candidate against influenza delivered nasally.
Product Name : ETH52
Product Type : Vaccine
Upfront Cash : Undisclosed
April 07, 2025
Lead Product(s) : ETH52
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Ethris
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : BV500
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : CF AMR Syndicate
Deal Size : $0.6 million
Deal Type : Funding
BioVersys gets Non-Dilutive Funds from CF AMR Syndicate Collaborative Discovery Programme
Details : The proceeds will support the development of novel small molecules targeting difficult to treat non-tubercular mycobacteria lung disease (NTM-LD) in people with cystic fibrosis (CF).
Product Name : BV500
Product Type : Antibiotic
Upfront Cash : Undisclosed
June 04, 2024
Lead Product(s) : BV500
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : CF AMR Syndicate
Deal Size : $0.6 million
Deal Type : Funding
Lead Product(s) : POL7306
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : CARB-X
Deal Size : $1.9 million
Deal Type : Funding
Details : The award will support the continuation of the "thanatin derivatives program" including POL7306, belonging to Spexis' novel Outer Membrane Protein Targeting Antibiotic class of antibiotics to potentially treat life-threatening infections.
Product Name : POL7306
Product Type : Peptide
Upfront Cash : Undisclosed
March 03, 2022
Lead Product(s) : POL7306
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : CARB-X
Deal Size : $1.9 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MTx’s DROPZYLLA® platform isolated ultra-rare and highly potent virus-neutralizing antibodies from COVID-19 patients within six weeks.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
April 06, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable